UK charity plugs drug R&D gap
Cancer Research Technology, a British cancer charity, is to fund clinical trials of a drug owned by GlaxoSmithKline (GSK), in a groundbreaking programme to develop promising experimental medicines that are neglected due to limited corporate funding.
Cancer Research Technology, a British cancer charity, is to fund clinical trials of a drug owned by GlaxoSmithKline (GSK), in a groundbreaking programme to develop promising experimental medicines that are neglected due to limited corporate funding.
The charity will shortly begin tests in patients of GSK's 1070916A an aurora kinase inhibitor. If the drug is successfully launched it will retain a share of the profits.
"GSK has got a large number of molecules in its pipeline and many merit investogation. But it can's take them all into the clinic at the same time so a numner end up sitting on the shelf," remarked Cancer Research's licensing manager, Ian Walker.
The charity will fund early and mid-stage testing in humans before offering GSk the opportunity to finance the more expensive late-stage clinical trials. If GSK decline, it may offer the rights to another company instead.
Terms of the agreement have not been disclosed.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
